| Unknown | Evaluate Safety and Efficacy of Rifamycin SV MMX in the Treatment of Traveler's Diarrhea in Children Age 6 to Traveler's Diarrhea | Phase 2 | 2024-06-01 |
| Unknown | Study to Evaluate Safety and Efficacy of Rifamycin SV MMX in Treating Traveler's Diarrhea in Children Age 12 t Traveler's Diarrhea | Phase 2 | 2024-01-01 |
| Terminated | Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease Covid19 | Phase 2 / Phase 3 | 2021-02-16 |
| Terminated | RHB-204 for the Treatment of Pulmonary Mycobacterium Avium Complex Disease Pulmonary Mycobacterium Avium Complex Infection, Bronchiectasis, Lung Diseases | Phase 3 | 2020-12-01 |
| Completed | Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia COVID-19, Lung Infection | Phase 2 / Phase 3 | 2020-08-21 |
| Withdrawn | Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen COVID-19, Lung Infection | Phase 1 / Phase 2 | 2020-08-01 |
| Completed | A Study of Opaganib in Coronavirus Disease 2019 Pneumonia Coronavirus Infections | Phase 2 | 2020-07-02 |
| Completed | A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar | Phase 2 | 2018-03-07 |
| Completed | ERADICATE Hp2 - Treating Helicobacter Pylori With RHB-105 Compared to Active Comparator Helicobacter Pylori Infection, Dyspepsia | Phase 3 | 2017-06-18 |
| Completed | Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn' Crohn Disease | Phase 3 | 2017-03-18 |
| Terminated | ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma Multiple Myeloma | Phase 1 / Phase 2 | 2016-12-13 |
| Completed | Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of BEKINDA (Ondansetron 12 mg Bimodal Release Table Irritable Bowel Syndrome With Diarrhea | Phase 2 | 2016-05-19 |
| Completed | BEKINDA (Ondansetron 24 mg Bimodal Release Tablets) for Vomiting Due to Presumed Acute Gastroenteritis or Gast Gastroenteritis, Gastritis | Phase 3 | 2014-12-08 |
| Withdrawn | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kapo Diffuse Large B Cell Lymphoma, Kaposi Sarcoma | Phase 1 / Phase 2 | 2014-07-01 |
| Completed | ERADICATE Hp - Treating Helicobacter Pylori With RHB-105 Dyspepsia, Helicobacter Pylori Infection | Phase 3 | 2013-11-01 |
| Completed | Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Crohn's Disease | Phase 3 | 2013-09-01 |
| Completed | Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Scle Relapsing Remitting Multiple Sclerosis | Phase 2 | 2013-06-01 |
| Completed | ABC294640 in Treating Patients With Advanced Solid Tumors Pancreatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | 2011-08-01 |
| No Longer Available | Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) Cholangiocarcinoma, Cholangiocarcinoma Non-resectable, Cholangiocarcinoma, Perihilar | — | — |